Cell penetrating peptides to target EIF4E

US9409961B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Waleed Danho · Del Mar, US
• Nader Fotouhi · Berkeley Heights, US
• Yi Han · Shanghai, CN
• Wajiha Khan · East Hanover, US
• Francesca Milletti · New York, US
• Huifeng Niu · Scotch Plains, US

Key dates

• Filing date: Jul 5, 2013
• Grant date: Aug 9, 2016
• Expiry date: Aug 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.